Portfolio Update

Summary by AI BETAClose X

EMV Capital plc announced a virtual "Meet the Portfolio" event scheduled for February 26, 2026, at 02:00 p.m. to provide investors with insights into two of its portfolio companies, Vortex, a leader in liquid biopsy technologies for precision oncology, and DName-iT, a MedTech company utilizing patented DNA barcoding for specimen labelling. The event, hosted on the Investor Meet Company platform, will feature presentations from the respective companies' leadership and EMV Capital's CEO, with questions able to be submitted in advance or during the live session. No inside information will be disclosed, adhering to UK Market Abuse Regulation.

Disclaimer*

EMV Capital PLC
12 February 2026
 

For announcement on Reach: 12 February 2026

 

EMV Capital plc

 

("EMVC" or the "Company")

 

Portfolio Update

 

As part of its ongoing investor engagement programme, EMV Capital plc (AIM: EMVC), the deep tech and life sciences VC investment group, is pleased to announce that it will host a virtual Meet the Portfolio event on 26 February 2026 at 02.00 p.m. The session will provide investors with greater insight into two of its portfolio companies, Vortex and DName-iT.

 

Virtual Meet the Portfolio - Vortex and DName-iT

 

The online event will take place via the Investor Meet Company platform and will be hosted by Dr Ilian Iliev, CEO of EMV Capital plc, who will be joined by:

·     The Managing Director of Vortex, a leader in liquid biopsy technologies for precision oncology; and

·     The CEO of DName-iT, a MedTech company applying its patented DNA barcoding method to develop a platform for labelling patients' specimens that are analysed with Next Generation Sequencing.

This presentation is open to all interested parties. Anyone can sign up for free and join the live presentation via:

https://www.investormeetcompany.com/emv-capital-plc/register-investor

Those who already follow the Company on the Investor Meet Company platform will automatically be invited.

Questions can be submitted pre-event via your Investor Meet Company dashboard up until 25 February 2026 at 09:00 a.m., or at any time during the live presentation.

In accordance with UK Market Abuse Regulation (UK MAR), no inside information will be disclosed during the event.

 

-Ends- 

 

For more information, please contact:

 

 

EMV Capital plc

via Rosewood

 

Ilian Iliev, CEO

 

 

 

Panmure Liberum Limited (NOMAD and Broker)

+44 (0)20 7886 2500

 

Emma Earl / Will Goode / Freddy Crossley / Mark Rogers (Corporate Finance)

 

 

Rupert Dearden (Corporate Broking)

 

 

 

Rosewood (Financial PR)

+44 (0)20 7653 8702

John West / Llewellyn Angus / Lily Pearce


 

 

About EMV Capital plc (EMVC)

 

EMV Capital plc, is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies.

With a strategic focus on generating superior returns for investors from the fast-growing sectors and technologies that will define our future; EMV Capital invests in, manages and strengthens early-stage IP-rich companies.

EMV Capital holds both direct equity stakes and carried interest in its portfolio companies, creating an evergreen structure that supports extensive growth and value creation. EMV Capital's investment thesis is realised through these capital sources:

·     capital-efficient investments through Group balance sheet;

·     fund management of the Evergreen EIS and Martlet Capital Funds;

·     syndicated investments leveraging its network of third-party investors.

EMV Capital's approach is characterised by its proactive management style, aiming to advance portfolio companies to critical value inflection points by actively engaging with them. Companies are supported through Board representation and the use of its Value Creation Services practice.

Headquartered in London, with a Cambridge presence and strong international links, EMV Capital is quoted on the AIM market of the London Stock Exchange.

www.emvcapital.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Emv Capital (EMVC)
UK 100

Latest directors dealings